Learn Why The Bull Case For Zenas BioPharma Stock Could Change Following Phase 3 Data

Simply Wall St.10-17

Zenas BioPharma reported new Phase 3 INDIGO data in IgG4-related disease, with obexelimab showing high 12 month flare free probabilities, low glucocorticoid rescue use, and adverse event rates ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676546255?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-17 14:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676546255","market":"hk","top_or_hot":-1,"title":"Learn Why The Bull Case For Zenas BioPharma Stock Could Change Following Phase 3 Data","media":"Simply Wall St.","content":"<div>\n<p>Zenas BioPharma reported new Phase 3 INDIGO data in IgG4-related disease, with obexelimab showing high 12 month flare free probabilities, low glucocorticoid rescue use, and adverse event rates ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/learn-why-the-bull-case-for-zenas-biopharma-stock-could-chan\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Learn Why The Bull Case For Zenas BioPharma Stock Could Change Following Phase 3 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLearn Why The Bull Case For Zenas BioPharma Stock Could Change Following Phase 3 Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-17 14:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/learn-why-the-bull-case-for-zenas-biopharma-stock-could-chan><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zenas BioPharma reported new Phase 3 INDIGO data in IgG4-related disease, with obexelimab showing high 12 month flare free probabilities, low glucocorticoid rescue use, and adverse event rates ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/learn-why-the-bull-case-for-zenas-biopharma-stock-could-chan\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBIO","symbol_name":"Zenas BioPharma Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/learn-why-the-bull-case-for-zenas-biopharma-stock-could-chan","article_id":"2676546255","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/learn-why-the-bull-case-for-zenas-biopharma-stock-could-chan","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676546255","pubTimestamp":1792218378,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Zenas BioPharma reported new Phase 3 INDIGO data in IgG4-related disease, with obexelimab showing high 12 month flare free probabilities, low glucocorticoid rescue use, and adverse event rates comparable to or lower than in the randomized period.\nThe firm also highlighted reduced glucocorticoid toxicity and preserved vaccine related immunity after long term obexelimab exposure, which speaks directly to treatment burden and long run care costs in autoimmune disease management.\nWe will now...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBIO":"Zenas BioPharma Inc.","BK4139":"生物科技"},"translate_title":"了解为什么 Zenas BioPharma 股票的牛市情况可能会在第三阶段数据后发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBIO":0.9},"content_text":"Zenas BioPharma reported new Phase 3 INDIGO data in IgG4-related disease, with obexelimab showing high 12 month flare free probabilities, low glucocorticoid rescue use, and adverse event rates comparable to or lower than in the randomized period. The firm also highlighted reduced glucocorticoid toxicity and preserved vaccine related immunity after long term obexelimab exposure, which speaks directly to treatment burden and long run care costs in autoimmune disease management. We will now examine how Zenas BioPharma's investment narrative could be affected by obexelimab's longer term flare protection profile.  Scan beyond Zenas BioPharma and this IgG4-RD update to uncover other autoimmune-focused opportunities in our hand picked 33 healthcare AI stocks. AdvertisementWhat Is Zenas BioPharma's Investment Narrative? Zenas BioPharma is a pure clinical story right now, so the big belief for any shareholder is simple. You need to think obexelimab can turn strong IgG4-RD data into real-world uptake, and that the broader autoimmune pipeline can justify ongoing cash burn before profitability. The new Phase 3 INDIGO extension data on flare protection, glucocorticoid toxicity and vaccine responses feeds directly into that thesis because it speaks to durability, treatment burden and everyday patient management rather than just short trial snapshots. In the near term, the key swing factors are execution heavy. Management has to turn a single lead asset, minimal reported revenue of about US$1m and ongoing losses into partnerships, approvals or both, while funding trials without repeating the substantial dilution already seen. The recent share price slide over the past month and quarter shows that good scientific headlines alone have not answered those concerns yet, even if this IgG4-RD update gives the story more clinical substance. That said, one issue still hangs over the Zenas BioPharma bull case that could matter far more than this IgG4-RD win... There's only one way to know the right time to buy, sell or hold Zenas BioPharma. Head to Simply Wall St's company report for the latest analysis of Zenas BioPharma's Fair Value. NasdaqGS:ZBIO 1-Year Stock Price Chart Exploring Other Perspectives Some of the most optimistic analysts frame this new obexelimab data as a potential revenue accelerator for Zenas BioPharma, even though their views were set before the symposium. They were already penciling in revenue of about US$414.5 million and earnings near US$71.5 million by 2029. Opinions may change as fresh results are released. Explore another Zenas BioPharma fair value estimate, including one that suggests potential upside of up to 138% from the current price. Decide For Yourself Don't just follow the ticker; dig into the data and build a conviction that's truly your own.  A great starting point for your Zenas BioPharma research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision. See our latest analysis for Zenas BioPharma. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Zenas BioPharma's overall financial health at a glance.  Looking For More Investment Ideas Beyond Zenas BioPharma? Once you have formed a view on Zenas BioPharma, it can help to broaden your watchlist with other opportunities that fit different risk, income, and balance sheet profiles using the Simply Wall St Screener.  If you want stocks that combine quality fundamentals with prices that may not fully reflect them, start with a curated set of 33 high quality undervalued stocks. For investors who care most about resilient cash flows and strong finances, filter for companies in the list of solid balance sheet and fundamentals (25 results). If you are hunting for under-the-radar opportunities with cleaner financial stories, scan through the 20 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zenas BioPharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676546255","isCrawlerRequest":true}